Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05669482
Title	Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (RAMP205)
Acronym	RAMP205
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	Verastem, Inc.
Indications	pancreatic ductal adenocarcinoma
Therapies	Defactinib + Gemcitabine + Nab-paclitaxel + RO5126766
Age Groups:	senior \| adult
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
UCSF Helen Diller Family Comprehensive Cancer Center	RECRUITING	San Francisco	California	94158	United States	Details
University of Chicago	RECRUITING	Chicago	Illinois	60637	United States	Details
Dana Farber Cancer Institute	RECRUITING	Boston	Massachusetts	02115	United States	Details
University of Michigan Cancer Center	RECRUITING	Ann Arbor	Michigan	48109	United States	Details
Washington University School of Medicine	RECRUITING	Saint Louis	Missouri	63110	United States	Details
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health	RECRUITING	New York	New York	10016	United States	Details
New York Presbyterian/Weill-Cornell Medical Center	RECRUITING	New York	New York	10021	United States	Details
Memorial Sloan Kettering Cancer Center	RECRUITING	New York	New York	10065	United States	Details
University of Pennsylvania	RECRUITING	Philadelphia	Pennsylvania	19104	United States	Details
University of Utah Huntsman Cancer Institute	RECRUITING	Salt Lake City	Utah	84112	United States	Details
Virginia Mason Medical Center	RECRUITING	Seattle	Washington	98101	United States	Details
Fred Hutchinson Cancer Center	RECRUITING	Seattle	Washington	98109	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field